ArticleBMC ophthalmology2026
The efficacy of MicroPulse Transscleral Laser Therapy as primary surgical treatment in various types of glaucoma resistant to medical treatment: a retrospective analysis.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the results of MicroPulse Transscleral Laser Therapy (TLT) as primary treatment in various types of glaucoma resistant to medical treatment.
methodsIn this retrospective study, the clinical outcomes of 118 eyes from 112 patients treated with MicroPulse TLT were evaluated. Intraocular pressure (IOP) values of patients with primary open-angle glaucoma (POAG), neovascular glaucoma (NVG), pseudoexfoliation glaucoma (PXG), pigmentary glaucoma (PG), angle-closure glaucoma (ACG), aphakic glaucoma (AG), congenital/juvenile glaucoma (PCG/JOAG) and silicone oil-induced glaucoma (SOG) treated with MicroPulse TLT were measured at baseline, 1 day, 1 week and 1, 3, 6 and 12 months (+/- 2 weeks) after application.
results79 eyes (66.9%) received single session MicroPulse TLT, 33 eyes (28.0%) received 2 sessions, and 6 eyes (5.1%) received 3 sessions. The initial treatment demonstrated a success rate of 72.8% (n = 86). 39 patients received a subsequent treatment, which elevated the overall success rate to 75.4% (n = 89) at 12 months. Significant reductions in IOP were observed in the POAG (46.5%), NVG (50.4%), PXG (43.7%), PG (52.7%), ACG (50.6%), AG (50.8%), PCG/JOAG (56.2%) and SOG (51%) groups up to 12 months compared to baseline (p < 0.05 for each). At the end of the 12th month, a 75.4% success rate was achieved with a 48.8% decrease in mean IOP in all groups. Consequently, the overall failure rate was 24.6% (n = 29).
conclusionAs a primary surgical treatment, MicroPulse TLT is an effective and safe, minimally invasive treatment method that reduces IOP and drug burden in various types of glaucoma resistant to medical treatment. Further large-scale, prospective studies are recommended to validate these findings and explore long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.